Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) and Veru (NASDAQ:VERU – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.
Profitability
This table compares Lexaria Bioscience and Veru’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lexaria Bioscience | N/A | -174.93% | -143.89% |
| Veru | N/A | -47.58% | -35.83% |
Analyst Recommendations
This is a summary of current ratings and target prices for Lexaria Bioscience and Veru, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lexaria Bioscience | 1 | 0 | 1 | 0 | 2.00 |
| Veru | 1 | 0 | 2 | 0 | 2.33 |
Institutional & Insider Ownership
13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 8.4% of Lexaria Bioscience shares are owned by company insiders. Comparatively, 14.2% of Veru shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Lexaria Bioscience has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Veru has a beta of -1.17, suggesting that its share price is 217% less volatile than the S&P 500.
Valuation & Earnings
This table compares Lexaria Bioscience and Veru”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lexaria Bioscience | $194,000.00 | 68.00 | -$11.90 million | ($5.10) | -1.56 |
| Veru | $16.89 million | 2.58 | -$22.73 million | ($0.69) | -3.70 |
Lexaria Bioscience has higher earnings, but lower revenue than Veru. Veru is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.
Summary
Veru beats Lexaria Bioscience on 9 of the 13 factors compared between the two stocks.
About Lexaria Bioscience
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
About Veru
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
